, Volume 176, Issue 2, pp 105-109
Date: 18 Apr 2007

Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Background

The chronic myeloproliferative disorders (MPD) are clonal haemopoietic stem cell disorders.

Aims

The incidence of JAK2 V617F mutation was sought in a population of patients with MPD.

Methods

The JAK2 V617 mutation status was determined in 79 patients with known MPD and 59 patients with features suggestive of MPD.

Results

The mutation was found in patients with polycythaemia vera, essential thrombocythaemia, idiopathic myelofibrosis and in patients with other chronic myeloproliferative disorders. Eight JAK2 V617F positive cases were identified amongst those patients with features suggestive of MPD.

Conclusions

The incidence of the JAK2 V617F mutation in MPD patients is similar to that reported by other groups. The assay confirmed and refined the diagnosis of several patients with features indicative of MPD. We suggest screening for this mutation in all patients with known and suspected MPD as identification is valuable in classification and is a potential target for signal transduction therapy.